Associations Between Sentinel Lymph Node Biopsy and Complications for Patients with Ductal Carcinoma In Situ

[1]  M. Toi,et al.  Paradigm Shift toward Reducing Overtreatment of Ductal Carcinoma In Situ of Breast , 2017, Front. Oncol..

[2]  F. Wärnberg,et al.  Risk of death from breast cancer after treatment for ductal carcinoma in situ , 2017, The British journal of surgery.

[3]  H. Kuerer,et al.  DCIS and axillary nodal evaluation: compliance with national guidelines , 2017, BMC Surgery.

[4]  P. Prorok,et al.  Breast-Cancer Tumor Size, Overdiagnosis, and Mammography Screening Effectiveness. , 2016, The New England journal of medicine.

[5]  F. Ahmed,et al.  A Nationwide Cross-Sectional Survey of UK Breast Surgeons' Views on the Management of Ductal Carcinoma In Situ , 2015, International journal of breast cancer.

[6]  A. Neugut,et al.  The Influence of Hospital and Surgeon Factors on the Prevalence of Axillary Lymph Node Evaluation in Ductal Carcinoma In Situ. , 2015, JAMA oncology.

[7]  H. Kuerer,et al.  Is Sentinel Lymph Node Dissection Warranted for Patients with a Diagnosis of Ductal Carcinoma In Situ? , 2015, Annals of Surgical Oncology.

[8]  I. Khansa,et al.  Analysis of Factors Contributing to Severity of Breast Cancer–Related Lymphedema , 2015, Annals of plastic surgery.

[9]  M. Edelman,et al.  Validation of Disability Status, a Claims-based Measure of Functional Status for Cancer Treatment and Outcomes Studies , 2014, Medical care.

[10]  Maureen A. Smith,et al.  Determining breast cancer axillary surgery within the surveillance epidemiology and end results‐Medicare database , 2014, Journal of surgical oncology.

[11]  E. Beckjord,et al.  Population-Level Trends in Posttreatment Cancer Survivors’ Concerns and Associated Receipt of Care: Results from the 2006 and 2010 LIVESTRONG Surveys , 2014, Journal of psychosocial oncology.

[12]  R. Sparapani,et al.  Surgeon specialization and use of sentinel lymph node biopsy for breast cancer. , 2014, JAMA surgery.

[13]  Maureen A. Smith,et al.  Impact of the American College of Surgeons Oncology Group (ACOSOG) Z0011 trial on Clinical Management of the Axilla in Older Breast Cancer Patients: A SEER-Medicare Analysis , 2013, Annals of Surgical Oncology.

[14]  Steven E Schild,et al.  Re: Proton vs intensity-modulated radiotherapy for prostate cancer: patterns of care and early toxicity. , 2013, Journal of the National Cancer Institute.

[15]  M. Edelman,et al.  A novel approach to improve health status measurement in observational claims-based studies of cancer treatment and outcomes. , 2013, Journal of Geriatric Oncology.

[16]  S. Sener,et al.  Identifying risk factors for surgical site infections in mastectomy patients using the National Surgical Quality Improvement Program database. , 2013, American journal of surgery.

[17]  B. Weiner,et al.  Differential receipt of sentinel lymph node biopsy within practice-based research networks. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  R. Kane,et al.  Ductal carcinoma in situ: risk factors and impact of screening. , 2010, Journal of the National Cancer Institute. Monographs.

[19]  R. Kane,et al.  Ductal carcinoma in situ of the breast: a systematic review of incidence, treatment, and outcomes. , 2010, Journal of the National Cancer Institute.

[20]  P. Austin.  Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples , 2009, Statistics in medicine.

[21]  E. Riedel,et al.  Prevalence of lymphedema in women with breast cancer 5 years after sentinel lymph node biopsy or axillary dissection: patient perceptions and precautionary behaviors. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  Kelly K Hunt,et al.  Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons Oncology Group Trial Z0011. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  J. Peterse,et al.  Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853--a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  Sheryl G. A. Gabram,et al.  Surgical Complications Associated With Sentinel Lymph Node Biopsy: Results From a Prospective International Cooperative Group Trial , 2006, Annals of Surgical Oncology.

[25]  E. Winer,et al.  American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  S. Duffy,et al.  Morbidity after sentinel lymph node biopsy in primary breast cancer: results from a randomized controlled trial. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  T. Tuttle,et al.  Trends in the treatment of ductal carcinoma in situ of the breast. , 2004, Journal of the National Cancer Institute.

[28]  E. Guadagnoli,et al.  Patient Demographic and Socioeconomic Characteristics in the SEER-Medicare Database: Applications and Limitations , 2002, Medical care.

[29]  Deborah Schrag,et al.  Overview of the SEER-Medicare Data: Content, Research Applications, and Generalizability to the United States Elderly Population , 2002, Medical care.

[30]  P D Cleary,et al.  Validating recommendations for coronary angiography following acute myocardial infarction in the elderly: a matched analysis using propensity scores. , 2001, Journal of clinical epidemiology.

[31]  R. D'Agostino.  Adjustment Methods: Propensity Score Methods for Bias Reduction in the Comparison of a Treatment to a Non‐Randomized Control Group , 2005 .

[32]  D. Tulsky,et al.  The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  J. Rasmussen,et al.  Recent progress in the treatment and prevention of cancer‐related lymphedema , 2015, CA: a cancer journal for clinicians.

[34]  Hodgkin Lymphoma.  NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines , 2014 .

[35]  Cary P Gross,et al.  Proton versus intensity-modulated radiotherapy for prostate cancer: patterns of care and early toxicity. , 2013, Journal of the National Cancer Institute.

[36]  R. Cicerone.  Initial National Priorities for Comparative Effectiveness Research , 2009 .

[37]  M. Fay,et al.  Costs of treatment for elderly women with early-stage breast cancer in fee-for-service settings. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  C. Steiner,et al.  Comorbidity measures for use with administrative data. , 1998, Medical care.

[39]  P. Austin.  American Journal of Epidemiology Practice of Epidemiology Statistical Criteria for Selecting the Optimal Number of Untreated Subjects Matched to Each Treated Subject When Using Many-to-one Matching on the Propensity Score , 2022 .